{"id":"NCT03150589","sponsor":"Samsung Bioepis Co., Ltd.","briefTitle":"A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)","officialTitle":"A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB11 and Lucentis® in Subjects With Neovascular Age-related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-14","primaryCompletion":"2019-05-24","completion":"2019-12-09","firstPosted":"2017-05-12","resultsPosted":"2021-05-21","lastUpdate":"2021-05-21"},"enrollment":705,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Age-Related Macular Degeneration"],"interventions":[{"type":"DRUG","name":"SB11 (Proposed ranibizumab biosimilar)","otherNames":[]},{"type":"DRUG","name":"Lucentis (ranibizumab)","otherNames":[]}],"arms":[{"label":"SB11 (Proposed ranibizumab biosimilar)","type":"EXPERIMENTAL"},{"label":"Lucentis (ranibizumab)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SB11 compared to Lucentis® in subjects with neovascular AMD.","primaryOutcome":{"measure":"Change From Baseline in Best Corrected Visual Acuity (BCVA)","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"SB11 (Proposed Ranibizumab Biosimilar)","deltaMin":6.26,"sd":0.51},{"arm":"Lucentis (Ranibizumab)","deltaMin":7.08,"sd":0.51}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":75,"countries":["United States","Czechia","Germany","Hungary","India","Poland","Russia","South Korea","United Kingdom"]},"refs":{"pmids":["36520462","33211076"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":350},"commonTop":["Nasopharyngitis","Intraocular pressure increased","Neovascular age-related macular degeneration","Hypertension","Visual acuity reduced"]}}